< Back to search
Filter
1

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

for
Recurrent Acute Myeloid Leukemia,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04140487

Phase1, Phase2, Recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

for
Recurrent Childhood Acute Myeloid Leukemia,
Location: Boston MA, New York NY, Philadelphia PA,
Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 18

Code: NCT06247787

Phase1, Recruiting

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

for
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 2 - 22

Code: NCT06128070

Phase2, Recruiting

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

for
Myelodysplastic Syndromes, Acute Myeloid Leukemia,
Location: White Plains NY, The Bronx NY, Sacramento CA
Sponsor: Montefiore Medical Center

Sex: All

Age: 18+

Code: NCT05184842

Phase2, Recruiting

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT05024552

Phase1, Recruiting

Interested in new acute myeloid leukemia trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

for
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia,
Location: Cincinnati OH, Birmingham AL, Nashville TN, Houston TX,
Sponsor: Vincerx Pharma, Inc.

Sex: All

Age: 18+

Code: NCT06034275

Phase1, Recruiting

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

for
Acute Monocytic Leukemia, Acute Myeloid Leukemia
Location: Miami FL, Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 18+

Code: NCT06504459

Phase2, Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

for
Acute Leukemia, Acute Lymphoblastic Leukemia,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 0+

Code: NCT04195633

Phase2, Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

for
Acute Myeloid Leukemia, Myelodysplastic Syndrome,
Location: Boston MA, Houston TX, Duarte CA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT03113643

Phase1, Recruiting

Venetoclax to Augment Epigenetic Modification and Chemotherapy

for
Acute Myeloid Leukemia, in Relapse,
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin

Sex: All

Age: 1 - 25

Code: NCT05317403

Phase1, Recruiting

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

for
Acute Myeloid Leukemia With Gene Mutations,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04493164

Phase2, Recruiting

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation,
Location: Boston MA, Worcester MA, New Haven CT, Stony Brook NY,
Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT05735184

Phase1, Recruiting

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

for
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Location: The Bronx NY
Sponsor: Montefiore Medical Center

Sex: All

Age: 18 - 70+

Code: NCT05342584

Phase1, Recruiting

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

for
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Location: Charlottesville VA, Rochester NY, Jacksonville FL,
Sponsor: Chordia Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05732103

Phase1, Phase2, Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

for
Acute Myeloid Leukemia (AML) in Remission
Location: Hackensack NJ, Philadelphia PA, Washington D.C. DC
Sponsor: Georgetown University

Sex: All

Age: 18+

Code: NCT04990102

Phase1, Phase2, Recruiting

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

for
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Location: Tampa FL, Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06616636

Phase1, Recruiting

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

for
Acute Myeloid Leukemia,
Location: Boston MA, Baltimore MD, Aventura FL, Chapel Hill NC,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT05886049

Phase1, Recruiting

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

for
Acute Myeloid Leukemia, IDH1 Mutation
Location: Miami FL
Sponsor: Justin Watts, MD

Sex: All

Age: 18 - 70+

Code: NCT06782542

Phase2, Recruiting

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

for
Acute Myeloid Leukemia,
Location: Boston MA
Sponsor: Eric Stephen Winer, MD

Sex: All

Age: 18+

Code: NCT05703542

Phase1, Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

for
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia,
Location: New York NY, Philadelphia PA, Durham NC, Toronto,
Sponsor: Syndax Pharmaceuticals

Sex: All

Age: 0+

Code: NCT04065399

Phase1, Phase2, Recruiting